Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...

Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, ...

Mizuho healthcare equity strategist Jared Holz joins Julie Hyman and Josh Lipton on Market Domination to analyze the GLP-1 ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...

摩根大通更新了一批可能在今年迎来上涨的生物制药公司名单，此前该行业的一些公司经历了一段冷热不均的时期。该机构在该领域的首选股票仍然是Eli Lilly。根据分析师Chris Scott的说法，Gilead Sciences和Bristol Myers ...

Drugmaker Eli Lilly plans to invest up to $27 billion to build four new pharmaceutical manufacturing sites in the U.S., the ...

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Eli Lilly and Company said Wednesday they plan to build new pharmaceutical manufacturing sites in the United States.